Your session is about to expire
← Back to Search
A Multi-center, Prospective Evaluation of Infants and Children With Congenital Ichthyosis
N/A
Waitlist Available
Led By Brittany Criaglow, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up birth (baseline), 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months, 36 months
Awards & highlights
No Placebo-Only Group
Summary
This project will follow babies with ichthyosis over time in order to better understand the natural course of ichthyosis in infants and children and to examine how specific genetic mutations affect clinical characteristics.
Eligible Conditions
- Ichthyosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ birth (baseline), 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months, 36 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~birth (baseline), 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months, 36 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Complications of Congenital Ichthyosis
Developmental Delays
Electrolyte Disturbance
+3 moreOther study objectives
Ear and Eye Conditions
Side effects data
From 2022 Phase 3 trial • 727 Patients • NCT0208540894%
White blood cell decreased
93%
Platelet count decreased
89%
Neutrophil count decreased
89%
Anemia
26%
Aspartate aminotransferase increased
22%
Alanine aminotransferase increased
19%
Creatinine increased
17%
Blood bilirubin increased
13%
Alkaline phosphatase increased
11%
Hypomagnesemia
9%
Febrile neutropenia
7%
Lymphocyte count decreased
4%
Lung infection
4%
Fatigue
4%
Hyperglycemia
4%
Urinary tract infection
4%
Diarrhea
2%
Investigations - Other, specify
2%
Colitis
2%
Hypoxia
2%
Pneumonitis
2%
Dyspnea
2%
Infections and infestations - Other
2%
Hyponatremia
2%
Hypokalemia
2%
Generalized muscle weakness
2%
Skin infection
2%
Eye disorders - Other, specify
2%
Pharyngitis
2%
Leukocytosis
2%
Thromboembolic event
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm F (Maintenance: Decitabine)
Arm B (Induction: Clofarabine)
Arm A (Induction: Daunorubicin + Cytarabine)
Arm C (Consolidation: Cytarabine)
Arm D (Consolidation: Clofarabine)
Arm E (Maintenance: Observation)
Arm G (Transplant)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: IchthyosisExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Yale UniversityLead Sponsor
1,930 Previous Clinical Trials
3,033,453 Total Patients Enrolled
1 Trials studying Ichthyosis
44 Patients Enrolled for Ichthyosis
Foundation for Ichthyosis & Related Skin Types (FIRST)UNKNOWN
Brittany Criaglow, MDPrincipal InvestigatorYale University